Skip to main content
Right Decisions for Health and Care
Right Decisions for Health and Care
Search for toolkits, guidelines and other information:
Search 'Polypharmacy guidance: realistic prescribing'...
Menu
All resources
Organisations
Learning & support
How to deliver RDS tools
Feedback
Right Decisions
Polypharmacy guidance: realistic prescribing
Efficacy (NNT)
Back
By Medicine
Direct Acting Oral Anticoagulants (DOACs)
Announcements and latest updates
test announcement
Print this page
Direct Acting Oral Anticoagulants (DOACs)
Polypharmacy guidance: realistic prescribing
Scottish Government Effective Prescribing & Therapeutics Division
About Direct Acting Oral Anticoagulants (DOACs)
Antiplatelet, placebo or no treatment
Apixaban 5mg twice daily vs Warfarin - stroke or systemic embolism
Apixaban 5mg twice daily vs Warfarin - major bleeding
Aspirin vs placebo or no treatment
Aspirin or other antiplatelet vs placebo or no treatment
Aspirin & Dipyridamole vs placebo
Aspirin & Dipyrdamole vs aspirin
Dabigatran 110mg or 150mg twice daily vs Warfarin - stoke or systemic embolism
Dabigatran 110mg or 150mg twice daily vs Warfarin- major bleeding
Edoxaban mg or 60mg daily vs Warfarin - stroke or systemic embolism
Edoxaban mg or 60mg daily vs Warfarin - major bleeding
Rivaroxaban 20mg daily vs Warfarin - stoke or systemic embolism
Rivaroxaban 20mg daily vs Warfarin - major bleeding
Statin vs placebo, stroke
Statin vs placebo, serious vascular events
Thienopyridine derivative (Ticlopidine or Clopidogrel) vs Aspirin, stroke (all types)
Thienopyridine derivative (Ticlopidine or Clopidogrel) vs Aspirin, stroke, MI or vascular death
Back to the top
Polypharmacy guidance: realistic prescribing
